Beyond medicines’ barriers: exploring the true cost of multiple myeloma

References

• International Myeloma Foundation. Who Gets Multiple Myeloma. 2019. [cited 2021 April 7]. https://www.myeloma.org/what-is-multiple-myeloma.
   Google Scholar
• Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221–1227.
   PubMed Web of Science ®Google Scholar
• Drummond M. Cost-of-Illness studies. Pharmacoeconomics. 1992;2(1):1–4.
   PubMedGoogle Scholar
• World Health Organization (WHO) Universal health coverage 2030 (UHC); 2022. https://www.uhc2030.org/
   Google Scholar
• United Nations (UN) Agenda 2030 Agenda for Sustainable Development. 2015. https://www.un.org/humansecurity/agenda-2030/
   Google Scholar
• European Medicines Agency (EMA). EMA Regulatory Science to 2025. EMA/110706/2020. 2020. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf
   Google Scholar
• EUnetHTA (European network for Health Technology Assessment). 2021. https://eunethta.eu/
   Google Scholar
• Hamadeh I, Atrash S, Matusz Fisher A, et al. Advances & future prospects in newly diagnosed multiple myeloma patients. Adv Cell Gene Ther. 2021;4(1):e96.
   Google Scholar
• Hepp R. Blood cancer care costs skyrocket for Medicare patients. Oncology Times. 2020;42(S2):9–10.
   Google Scholar
• Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653–671.
   PubMed Web of Science ®Google Scholar
• Critical Appraisal Skills Programme 2018. CASP Economic Evaluation Checklist. [online]. https://casp-uk.net/wp-content/uploads/2018/03/CASP-Economic-Evaluation-Checklist-2018_fillable_form.pdf.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, The PRISMA Group, et al. Preferred reporting items for systematic reviews and MetaAnalyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Ashcroft J, Judge D, Dhanasiri S, et al. Chart review across EU5 in MM post-ASCT patients. Int J Hematol Oncol. 2018;7(1):IJH05.
   PubMedGoogle Scholar
• Gonzalez-McQuire S, Yong K, Leleu H, et al. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. J Med Econ. 2018;21(5):450–467.
   PubMed Web of Science ®Google Scholar
• Thompson JF, Teh Z, Chen Y, et al. A costing study of bortezomib shows equivalence of its real-world costs to conventional treatment. Br J Haematol. 2020;189(3):e76–e79.
   PubMed Web of Science ®Google Scholar
• Jackson G, Galinsky J, Alderson DEC, et al. Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy. Eur J Haematol. 2019;103(4):393–401.
   PubMed Web of Science ®Google Scholar
• Robinson D, Jr Orlowski RZ, He J, et al. Economic burden of relapsed or refractory multiple myeloma: results from an international trial. Blood. 2015;126(23):875–875.
   Web of Science ®Google Scholar
• Holbro A, Ahmad I, Cohen S, et al. Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2013;19(4):547–551.
   PubMed Web of Science ®Google Scholar
• Touati M, Lamarsalle L, Moreau S, et al. Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in outpatient hospital and hospital care at home. Support Care Cancer. 2016;24(12):5007–5014.
   PubMed Web of Science ®Google Scholar
• Martino M, Pellicano G, Moscato T, et al. At-home management of aplastic phase following high-dose melphalan and autologous haematopoietic stem cell transplantation for multiple myeloma patients: a pilot study. Blood. 2011;118(21):4497.
   Google Scholar
• Kodad SG, Sutherland H, Limvorapitak W, et al. Outpatient autologous stem cell transplants for multiple myeloma: Analysis of safety and outcomes in a tertiary care center. Clin Lymphoma Myeloma Leuk. 2019;19(12):784–790.
   PubMed Web of Science ®Google Scholar
• Lassalle A, Thomaré P, Fronteau C, et al. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study. Ann Oncol. 2016;27(2):314–318.
   PubMed Web of Science ®Google Scholar
• Nikonova A, Zeglinski C, Husain S, et al. Infectious complications in the outpatient and inpatient autologous stem cell transplantation setting for patients with multiple myeloma. Princess Margaret Cancer Center Experience. Blood. 2018;132(Suppl 1):4614–4614.
   Google Scholar
• Martino M, Console G, Russo L, et al. Autologous stem cell transplantation in patients with multiple myeloma: an activity-based costing analysis, comparing a total inpatient model versus an early discharge model. Clin Lymphoma Myeloma Leuk. 2017;17(8):506–512.
   PubMed Web of Science ®Google Scholar
• Kolovos S, Nador G, Kishore B, et al. Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs. J Bone Oncol. 2019;17:100243.
   PubMed Web of Science ®Google Scholar
• de Oliveira C, Cheng J, Chan K, et al. High-Cost patients and preventable spending: a Population-Based study. J Natl Compr Canc Netw. 2020;18(1):23–31.
   PubMed Web of Science ®Google Scholar
• Robinson D, Jr Orlowski RZ, Stokes M, et al. Economic burden of relapsed or refractory multiple myeloma: Results from an international trial. Eur J Haematol. 2017;99(2):119–132.
   PubMed Web of Science ®Google Scholar
• Wong R, Tay J. Economics of multiple myeloma. Blood. 2018;132(Suppl 1):4773–4773.
   Google Scholar
• Ashcroft J, Duran I, Hoefeler H, et al. Healthcare resource utilisation associated with skeletal‐related events in european patients with multiple myeloma: Results from a prospective, multinational, observational study. Eur J Haematol. 2018;100(5):479–487.
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Baldomero H, Atsuta Y, et al. The global state of hematopoietic stem cell transplantation for multiple myeloma: an analysis of the worldwide network of blood and marrow transplantation (WBMT) database and the global burden of disease study. Blood. 2019;134(Supplement_1):412.
   Google Scholar